Learn About Hajdu-Cheney Syndrome

What is the definition of Hajdu-Cheney Syndrome?

Hajdu-Cheney syndrome is a rare disorder that can affect many parts of the body, particularly the bones. Bone loss from the tips of the fingers and toes (acroosteolysis) is a characteristic feature of the condition. The fingers and toes may appear short and rounded, and they may become shorter over time as the bone continues to break down. In people with Hajdu-Cheney syndrome, the fingers are more likely to be affected than the toes. Bone loss in the fingers can interfere with fine motor skills, such as picking up small objects.

What are the causes of Hajdu-Cheney Syndrome?

Hajdu-Cheney syndrome is associated with variants (also called mutations) in the NOTCH2 gene. This gene provides instructions for making a receptor protein. Other proteins, called ligands, can fit into specific sites on receptor proteins, like a key into a lock. When a ligand binds to the NOTCH2 receptor protein, it triggers a signaling pathway called the NOTCH2 signaling pathway. NOTCH2 signaling is important for the early development of bones and for bone remodeling, a normal process in which old bone is removed and new bone is created to replace it. NOTCH2 signaling also appears to be involved in the development of the heart, kidneys, teeth, and other parts of the body.

How prevalent is Hajdu-Cheney Syndrome?

Although Hajdu-Cheney syndrome is a rare disease, its exact prevalence is unknown. Fewer than 100 affected individuals have been described in the medical literature.

Is Hajdu-Cheney Syndrome an inherited disorder?

Hajdu-Cheney syndrome is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Many cases of this condition result from a new (de novo) variant in the gene that occurs during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or during early embryonic development. These affected individuals typically have no history of the disorder in their family.

Who are the top Hajdu-Cheney Syndrome Local Doctors?
Elite in Hajdu-Cheney Syndrome
Elite in Hajdu-Cheney Syndrome

Dysautonomia Center Llp

530 1st Ave, Suite 9q, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Horacio Kaufmann is a Neurologist in New York, New York. Dr. Kaufmann is rated as an Elite provider by MediFind in the treatment of Hajdu-Cheney Syndrome. His top areas of expertise are Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, and Orthostatic Hypotension.

Elite in Hajdu-Cheney Syndrome
Elite in Hajdu-Cheney Syndrome
Zurich, ZH, CH 

Thorsten Hornemann practices in Zurich, Switzerland. Mr. Hornemann is rated as an Elite expert by MediFind in the treatment of Hajdu-Cheney Syndrome. His top areas of expertise are Hereditary Sensory Neuropathy Type 1 (HSN1), Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, Anhidrosis, and Gastric Bypass.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hajdu-Cheney Syndrome
Elite in Hajdu-Cheney Syndrome
Aachen, NW, DE 

Ingo Kurth practices in Aachen, Germany. Mr. Kurth is rated as an Elite expert by MediFind in the treatment of Hajdu-Cheney Syndrome. His top areas of expertise are Hajdu-Cheney Syndrome, Hereditary Sensory and Autonomic Neuropathy Type 2, Hereditary Sensory Neuropathy Type 1 (HSN1), Anhidrosis, and Bone Marrow Transplant.

What are the latest Hajdu-Cheney Syndrome Clinical Trials?
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors

Summary: This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

Match to trials
Find the right clinical trials for you in under a minute
Get started
Natural History of Familial Dysautonomia

Summary: The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment. This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test ...

Who are the sources who wrote this article ?

Published Date: December 15, 2025
Published By: National Institutes of Health